UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 1, 2019
Simlatus Corp.
(Exact name of Company as specified in its charter)
| Nevada | 000-53276 | 20-2675800 |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of Incorporation) | Identification Number) |
|
175
Joerschke Dr., Suite A
|
| (Address of principal executive offices) |
|
Phone: (530) 205-3437 |
| (Company’s Telephone Number) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
Purchase Order for Proscere Biosciences Cold-Water CBD Extraction Systems with Alcohol on July 31, 2019.
Pursuant with the distribution agreement with United Opportunities, LLC, where as on March 29, 2019, the Company and its subsidiary, Proscere Bioscience Inc., entered into a Distribution Agreement with United Opportunities, LLC allowing the rights to sell the Cold Water CBD Extraction Systems with Alcohol within Canada and Europe; the company received a commercial purchase order from United Opportunities, LLC on July 31, 2019 to manufacture 4 Cold-Water CBD Extraction Systems with Alcohol for one of their customers in the amount of $16,945,668. After manufacturing and delivery, the net profit is approximately $8.4 M. The term of the Agreement with United Opportunities, LLC is for five years with guaranteed minimal purchase orders of $35,000,000 per year and/or $175,000,000 over a Five year period.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 1, 2019
Simlatus Corporation
| /s/ Richard Hylen |
| By: Richard Hylen, CEO and Chairman |